Episode
CRISPR’s Hidden Value Amid Stock Dip
- Published
- Jun 8, 2026
- Duration seconds
- 141
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/crispr-s-hidden-value-amid-stock-dip/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/crispr-s-hidden-value-amid-stock-dip.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
CRISPR Therapeutics holds a blockbuster gene-editing therapy, Casgevy, approved for blood disorders and already treating 500+ patients at a $2.2M price tag—yet its stock trades 40% below analyst estimates. Despite Nobel-winning tech and a pipeline targeting diabetes, heart disease, and more, investors hesitate due to high costs, delayed revenue recognition, and profit-sharing with Vertex. A recent $600M raise risks dilution, but the long-term upside is massive: analysts see a much higher price target, and the company remains a prime acquisition target as the gene-editing field surges. It’s a high-risk, high-reward biotech bet—waiting for the market to believe the science will soon pay off. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/d36ccb29d00f5984